4D Molecular Therapeutics, Inc.
FDMT Nasdaq
SEC CIK 1650648
Follow 4D Molecular Therapeutics
Weekly email: filings, results
Revenue, last quarter
$4.1M
+4505.6% vs same quarter last year
Net income
−$78.1M
−37.2% vs same quarter last year
EPS, diluted
−$1.08
−6.9% vs same quarter last year
Operating cash flow
−$56.7M
−22% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $85.2M | −$140.1M |
| FY24 | $37K | −$160.9M |
| FY23 | $20.7M | −$100.8M |
| FY22 | $3.1M | −$107.5M |
| FY21 | $18M | −$71.3M |
| FY20 | $13.4M | −$56.7M |
| FY19 | $7M | −$49.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −187.2% | −164.4% |
| FY24 | −507678.4% | −434778.4% |
| FY23 | −544.6% | −486.6% |
| FY22 | −3516.5% | −3435.4% |
| FY21 | −395.5% | −395.4% |
| FY20 | −424% | −424.3% |
| FY19 | −729.4% | −708.4% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$109.6M |
| FY24 | −$138.4M |
| FY23 | −$78.6M |
| FY22 | −$98.2M |
| FY21 | −$78.2M |
| FY20 | −$51.9M |
| FY19 | −$39.9M |
| FY18 | - |
- 4D Molecular Therapeutics
- Healthcare median
Show the numbers
| Year | 4D Molecular Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −164.4% | −30.6% |
| FY24 | −434778.4% | −47% |
| FY23 | −486.6% | −58% |
| FY22 | −3435.4% | −80.4% |
| FY21 | −395.4% | −71.8% |
| FY20 | −424.3% | −62.2% |
| FY19 | −708.4% | −46.2% |
| FY18 | - | −49.6% |